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Prolonging Nephrogenesis in Preterm Infants
A New Approach for Prevention of Kidney Disease in Adulthood?
Vassilios Fanos,1 Massimo Castagnola,2 Gavino Faa3
Chronic kidney disease represents a dramatic worldwide resource-
consuming problem. This problem is of increasing importance 
even in preterm infants, since nephrogenesis may go on only for 
a few weeks (4 to 6 weeks) after birth. Recent literature focusing 
on traditional regenerative medicine does not take into account the 
presence of a high number of active endogenous stem cells in the 
preterm kidney, which represents a unique opportunity for starting 
regenerative medicine in the perinatal period. Pluripotent cells of the 
blue strip have the capacity to generate new nephrons, improving 
kidney function in neonates and potentially protecting them from 
developing chronic kidney disease and end-stage renal disease in 
adulthood. There is a marked interindividual neonatal variability 
of nephron numbers. Moreover, the renal stem/progenitor cells 
appear as densely-packed small cells with scant cytoplasm, giving 
rise to a blue-appearing strip in hematoxylin-eosin–stained kidney 
sections (“the blue strip”). There are questions concerning renal 
regenerative medicine: among preliminary data, the simultaneous 
expression of Wilms tumor 1 and thymosin β4 in stem/progenitor 
cells of the neonatal kidney may bring new prospects for renal 
regeneration applied to renal stem cells that reside in the kidney 
itself. A potential approach could be to prolong the 6 weeks of 
postnatal renal growth of nephrons or to accelerate the growth of 
nephrons during the 6 weeks or both. Considering what we know 
today about perinatal programming, this could be an important 
step for the future to reduce the incidence and global health impact 
of chronic kidney disease.
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INTRODUCTION
Chronic kidney disease (CKD) represents a 
global public health issue with different features to 
take into account in different parts of the world.1 
The prevalence of end-stage renal disease (ESRD) 
is increasing dramatically during the last years.2 
According to the 2010 Global Burden of Disease 
study, CKD was ranked 27th in the list of causes 
of total number of global deaths in 1990, but rose 
up to 18th in 2010, with a annual death rate of 16.3 
per 100 000.3 Despite the magnitude of resources 
designated to the therapy of patients affected by 
ESRD and the improvements in the quality of 
dialysis therapy, these patients experience a reduced 
quality of life, associated with high mortality.4 
Children undergoing kidney transplantation, thanks 
to the improvements in antirejection therapy, have 
a 95% chance of surviving at 5 years, but their 
long-term survival rate lowers to 79% at 10 years 
and 66% at 20 years.5 These data clearly indicate 
that kidney transplantation does not represent the 
definitive therapy for ESRD. 
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Regenerative medicine has made remarkable 
progress in recent years, with the development 
of techniques to mobilize and activate renal stem 
cells in injured kidneys or to introduce exogenous 
stem cells for tissue repair.6 Unfortunately, when 
the complex kidney structure is disrupted by 
ESRD, traditional stem cell-based approach has 
been demonstrated to be unable to regenerate 
the damaged organ. Whole kidney “de novo” 
regeneration may be considered a promising 
therapeutic approach for patients with ESRD.7 Taken 
together, these data suggest that change—discarding 
old approaches and giving opportunity to new 
therapies—is a mandate, focusing on prevention 
of CKD insurgence when the kidney architecture 
is still preserved. The theme of this article is the 
introduction of a new potential approach for the 
prevention of CKD, based on the utilization of a 
previously unrecognized physiological regenerative 
source: the huge amount of stem cells that are 
present in the kidney of preterm infants at birth.
VARIABILITY OF NEPHRON NUMBERS 
The number of nephrons in the kidney of adults 
is characterized by a marked interindividual 
variability, ranging almost 9 fold from about 200 000 
up to 1 800 000 or more, nephron burden being 
inversely related to body weight at birth.8 Nephron 
number at birth is conditioned by the intrauterine 
environment, the 9 months of gestation permanently 
influencing the number of developed functional 
glomeruli. Since nephrogenesis ends around the 36th 
week of gestation, the nephron number detectable 
at birth will be stable during life. As a consequence, 
events occurring during the early steps of kidney 
development set lifelong trajectories, raising or 
lowering risk of developing kidney failure later in 
life. Considering 2 individuals at the extremes of the 
spectrum, carrying 200 000 and 1 800 000 nephrons 
respectively, the clinical significance of a noxa 
destroying 100 000 nephrons could be completely 
different in these individuals.9 Preterm infants, 
given their low nephron number,10 are considered 
at a higher risk of congenital oligonephronia, as 
well as low birth weight neonates, linking body 
weight at birth with the susceptibility to develop 
CKD in adulthood.11 
PERINATAL KIDNEY 
Kidneys in preterm newborns show relevant 
functional and structural differences as compared 
to term newborns. Kidney function in the neonate 
differs quantitatively from that in older children. 
Although a full complement of nephrons is present 
at 34 weeks of gestation, glomerular and tubular 
function continue to mature during the 1st year of 
life. In the human, nephrogenesis is complete at 36 
weeks of fetal gestation, so that full term newborn 
infants have as many nephrons as they will have 
for the rest of their life, but a prematurely born 
infant will continue to produce new nephrons for 
sometime after birth (4 to 6 weeks), depending on 
the neonate gestational age. A marked increase in 
renal perfusion may contribute to these changes. 
Following delivery, the loss of placental renal 
blood flow is only 3% to 5% of the cardiac output, 
as compared to approximately 20% in the infants 
and children. The next phase of growth is the 
anatomical maturation of the nephrons already 
present. Thus, there are changes in glomerular and 
tubular histology that could theoretically affect 
kidney function. Included in this phase of renal 
growth are biochemical changes in the renal cells.9-13 
Despite its incomplete maturation, the newborn 
kidney is functional and glomerulotubular balance 
is intact. Thus, the presence of “immature” kidneys 
should not be used to explain disturbances in fluid 
and electrolyte balance or kidney dysfunction.
The presence of a huge amount of stem/
progenitor cells in close proximity of the renal 
capsule represents the most important peculiar 
feature of the fetal kidney, and it is the focus 
of our work.12 The renal stem/progenitor cells 
appear as densely-packed small cells with scant 
cytoplasm, giving rise to a blue-appearing strip in 
hematoxylin-eosin–stained kidney sections. After 
birth, nephrogenesis may go on only for 4 to 6 weeks, 
and then it stops.12 As a consequence, in a preterm 
infant born at 26 weeks, nephrogenesis will stop 
for example at the 32nd postconceptional week, 
linking prematurity with oligonephronia and with 
higher susceptibility of preterm infants to develop 
kidney disease later in life. If this newborn has 
suffered intrauterine growth restriction in the womb 
or acute kidney injury postnatally, this interval of 
nephrogenesis will be even more reduced.
REGENERATIVE MEDICINE 
Concept
The presence of a high number of active 
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endogenous stem cells in the preterm kidney 
represents a unique opportunity for starting 
regenerative medicine in the perinatal period. 
Pluripotent cells of the blue strip have the capacity to 
generate new nephrons, improving kidney functions 
in neonates and protecting them from developing 
CKD and ESRD in adulthood. The main obstacle for 
the actual utilization of this regenerative potential is 
the abrupt interruption of their nephrogenic activity a 
few weeks after birth in preterm infants, irrespective 
of the gestational age at birth. To understand how 
to switch on stem/progenitors of the blue strip, 
maintaining their activity in the generation of 
new nephrons till the 36th postconceptional week 
represents the new challenge for the prevention of 
CKD in adulthood. Dealing with endogenous stem 
cells physiologically present in the fetal kidney, we 
defined this new approach as “physiological renal 
regenerative medicine.13,14”
Open Questions Concerning Renal 
Regenerative Medicine
Some questions should be raised regarding this 
new approach to kidney regeneration early in life:
(1) W h y  r e s e a r c h e r s  i n v o l v e d  i n  k i d n e y 
regeneration did not consider this relevant 
endogenous renal stem burden?
(2) W h y  t h e  l i t e r a t u r e  r e g a r d i n g  k i d n e y 
development has been exclusively focused 
on factors blocking nephrogenesis (brake) 
and not on factors favoring an optimal 
glomerulogenesis (accelerator)?
(3) Which is the way to follow for activating renal 
progenitors of the blue strip, forcing them to 
continue or accelerating nephron production 
till the 35th or 36th postconceptional week, 
reducing the gap in nephron number between 
preterm and at term newborns?
It is evident that traditional renal regenerative 
medicine is unable to solve the problem of kidney 
failure or to alleviate patients with ESRD. In our 
opinion, one of the major obstacles for a successful 
renal regeneration in adults has been the application 
of regenerative techniques to severely injured 
kidneys; moreover, the introduction of exogenous 
stem cells is unable to completely regenerate the 
totally disrupted renal tissue.7 The major advantages 
of the application of regenerative techniques to 
newborn with a low nephron burden at birth are 
here listed:
(1) To avoid the ethical problems associated with 
the manipulation of germ cells in producing 
embryonic stem cells15;
(2) To bypass the use of retroviral transduction 
in the generation of induced pluripotent 
stem cells and the risk related to our limited 
understanding of its effects16; 
(3) To avoid the use of donor bone marrow-derived 
stem cells, with limitations due to rarity of 
their migration into the affected kidney and 
to their limited ability to trans-differentiate17;
(4) To avoid the use of mesenchymal stem cells 
from adipose tissue of CKD patients, often 
inappropriate for renal regeneration due to 
functional incompetence induced by uremia18; 
and
(5) To avoid the ethical issues related to the use 
of heterologous animals including porcine 
precursors in the efforts to regenerate “de 
novo” a whole functional kidney.19
The answer to our 2nd question regards the 
inability of perinatologists to evaluate all the factors 
that may influence the delicate equilibrium of kidney 
growth and development during gestation. Great 
attention has been devoted to the factors lowering 
the nephron number, which are able to modify 
the equilibrium between mitosis (accelerator) and 
apoptosis (brake), downregulating renal stem cell 
survival and differentiation, and ending with a 
modified kidney development.20 In the opinion of 
the authors, more attention should be devoted to 
defining all factors stimulating stem cell survival 
and differentiation during gestation, which enable 
us to accelerate nephrogenesis particularly in 
the perinatal period. In this new approach, the 
developing kidney should be seen as the optimal 
source of stem/pluripotent cells to be implemented 
by favorable  epigenet ic  factors ,  including 
adequate caloric intake and proper vitamins and 
normoxia, and avoiding nephrotoxic drugs, such 
as aminoglycosides, glycopeptides, nonsteriod 
anti-inflammatory drugs, and amphotericin.21 
The knowledge of all factors able to improve 
nephrogenesis after birth could represent a powerful 
tool in the hands of neonatologists, allowing them 
to restore nephron deficit in preterm infants and 
newborns with intrauterine growth retardation, 
the two clinical settings typically associated with 
congenital oligonephronia.
The 3rd question regards the possible clinical 
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approach aimed at ameliorating and prolonging 
nephrogenesis after birth. Our goal is the definition 
of a new target therapy, aimed at prolonging 
nephrogenesis after birth in all neonates with a 
low nephron burden. There is a crucial period 
postnatally where nephrogenesis continues in 
preterm neonates. This period is normally about 
6 weeks long, but it can be shorter in newborns 
affected by acute kidney injury or with intrauterine 
growth retardation.
New Perspectives
Our proposal is based on a better comprehension 
of the molecular pathways regulating renal 
stem/progenitor cells survival and function in 
the perinatal period, with particular attention to 
preterm newborns.22
Recent evidence that paracrine stimulation 
u n d e r l i e s  t h e  f u n c t i o n a l  b e n e f i t s  i n  c e l l 
transplantat ion led to a  paradigm shift  in 
regenerative medicine: from cell therapy to 
factor/protein-based regenerative therapy, future 
regenerative approaches likely involving the 
definition of synergistic protein cocktails specific 
for each organ.23 The basis for the development of 
a new nephrogenic protein-based therapy is the 
definition of the protein markers expressed by 
the renal progenitors operating in the blue strip. 
Previous papers from our group showed that renal 
precursors show a peculiar immunohistochemical 
pattern as compared to stem/progenitor cells 
in other organs.23 Immunohistochemistry of the 
nephrogenic zone is characterized by expression of 
Wilms tumor 1 (WT1),24 paired box protein-2, CD44, 
B-cell lymphoma-2, thymosin β10,25,26 thymosin β4 
(Tβ4), and nucleotide sugar epimerase (personal 
unpublished data). Comprehensive profiling of 
human renal stem cells includes the expression 
of markers such as CD24, CD133, NCAM, and 
EpCAM.27
Among these preliminary data on the profiling 
of human renal stem cells, the contemporary 
expression of WT1 and Tβ4 in the stem/progenitor 
cells of the human embryo kidney deserves, in our 
opinion, some consideration regarding the research 
on stimuli that could initiate the formation of 
new nephrons in the neonatal kidney after birth. 
Thymosin β4 is expressed in multiple embryonic 
human tissues, including salivary glands,28 the 
embryonic heart,29 and the developing kidney.30 
In the embryo heart, Tβ4 is essential to initiate 
embryonic coronary developmental program 
by stimulating cardiomyocytes migration and 
promoting cardiac cell survival.31 At molecular 
level, Tβ4 initiates protein kinase C inducing an 
organ-wide epicardial thickening and activation 
of progenitor cells, while initiating the expression 
of numerous pro-angiogenic genes.32 The stem or 
progenitor cell population, thought to be derived 
from the epicardium, are targeted and activated 
by Tβ4 even in the adult heart, restoring their 
vascular potential via re-expression of the key 
embryonic epicardial gene, WT1, resulting in their 
mobilization and differentiation to give rise to de 
novo cardiomyocytes.33 The beneficial effects of 
Tβ4 on cardiomyocytes regeneration is related to 
its ability to form a complex with integrin-linked 
kinase, resulting in the activation of survival kinase 
Akt, which stimulates production of vascular 
endothelial growth factor.34 Cardiomyocytes 
derived from Tβ4-activated epicardial cells 
have been shown to functionally integrate with 
resident cardiomyocytes to regenerate functional 
myocardium.35 Taken together, these data indicate 
that the simultaneous expression of WT1 and Tβ4 in 
stem/progenitor cells of the neonatal kidney may 
bring new prospects for renal regeneration applied 
to renal stem cells that reside in the kidney itself.
CONCLUSIONS 
Chronic kidney disease represents a dramatic 
worldwide resource-consuming problem. It is 
difficult to define histologically what is normal 
and what is not, taking into the account the 
enormous variability of the number of nephrons 
at birth in apparently healthy individuals. All 
efforts must be promoted to enhance protective 
factors or minimize aggressive factors in preterm 
developing kidneys. A potential approach could 
be to prolong the 6 weeks of postnatal renal 
growth of nephrons or to accelerate the growth of 
nephrons during the 6 weeks or both. A tailored 
approach could be hypothesized in the future, 
taking into account all information on the kidney 
and renal regenerative medicine. In this setting, 
the simultaneous expression of WT1 and Tβ4 
in stem/progenitor cells of the neonatal kidney 
may bring new prospects for renal regeneration 
applied to renal stem cells that reside in the kidney 
itself. Modulating these main actors in the renal 
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scenario, it is perhaps possible to look at old data 
with new approaches, favoring endogenous renal 
stem cell’s mitosis, blocking apoptosis and giving 
the possibility to preterm newborns to improve 
their final number of nephron. Considering what 
we know today about perinatal programming, 
this could be an important step for the future to 
reduce incidence and global health impact of CKD.
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